Autologous CD133-positive BTSC mRNA-pulsed autologous dendritic cell vaccine

{
  "id": "MLC-T-ONC-011532",
  "term": "Autologous CD133-positive BTSC mRNA-pulsed autologous dendritic cell vaccine",
  "field": "Oncology and biomedicine",
  "definition": "A cancer vaccine consisting of autologous dendritic cells (DCs) loaded with CD133-positive autologous brain tumor stem cells (BTSCs) - derived mRNA with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, autologous CD133-positive BTSC mRNA-pulsed autologous dendritic cell vaccine may elicit a cytotoxic T-lymphocyte (CTL) response against the CD133-positive BTSCs from which the autologous tumor mRNA is derived. CD133, a tumor-associated antigen (TAA) and neural stem cell marker, has been found on a specific subset of glioblastoma multiforme (GBM) stem cells; its presence has been correlated with resistance to conventional chemotherapy and radiotherapy.",
  "synonyms": [
    "autologous CD133-positive brain tumor stem cell mRNA-pulsed autologous dendritic cell vaccine"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-cd133-positive-btsc-mrna-pulsed-autologous-dendritic-cell-vaccine/"
}